Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

These Guidelines represent the third time that the ESC and EACTS have brought together
cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body …

always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …

Background Drug-coated balloons (DCB) are a novel therapeutic strategy for small native
coronary artery disease. However, their safety and efficacy is poorly defined in comparison …

Background In the treatment of de-novo coronary small vessel disease, drug-coated
balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up …

Zachęca się pracowników opieki zdrowotnej, aby w pełni uwzględniali te wytyczne
ESC/EACTS, gdy dokonują oceny klinicznej, a także kiedy określają i realizują medyczne …

Percutaneous coronary intervention with a drug-eluting stent is the most common mode of
revascularization for coronary artery disease. However, restenosis rates remain high. Non …

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the world.
Central to the pathogenesis of CAD is the development of atherosclerotic lesions in coronary …

Background The optimal technique of percutaneous coronary intervention in patients at high
bleeding risk is not known. The hypothesis of the DEBUT trial was that percutaneous …

Nonstent-based local drug delivery during percutaneous intervention offers potential for
sustained antirestenotic efficacy without the limitations of permanent vascular implants …